Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Bio's Q1 Revenues Rise on Instrument Sales

NEW YORK (GenomeWeb News) – Pressure BioSciences today reported that its first-quarter revenues increased to $306,762 from $132,376 year over year.

The firm said that sales of its Pressure Cycling Technology products and services were $222,142 versus $81,473 in the comparable quarter of 2008. Pressure Bio said the sales growth was driven by the installation of 10 Barocycler instruments during the quarter, compared to seven such sales in Q1 2008.

Richard Schumacher, president and CEO of Pressure Bio, said that the firm has "now reported three consecutive quarters of double-digit growth of PCT Sample Preparation installations."

The firm's net loss for the quarter was $224,246, or $.10 per share, compared to a net loss of $1.3 million, or $.61 per share, for the first quarter of 2008.

Its R&D costs fell to $307,224 from $490,931 year over year, while its SG&A spending dropped to around $790,000 from $964,000.

Pressure Bio finished the quarter with $2.1 million in cash and cash equivalents.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.